NEW YORK (GenomeWeb News) – BGI and H3 Biomedicine today announced they will sequence and publish data from next-generation sequencing-based research on pre-clinical cancer models.

In the first study to be performed under the terms of the partnership, BGI will sequence 250 cancer cell lines using next-generation whole-exome sequencing. It and H3 Biomedicine will jointly analyze the data and then deliver a highly curated set of "genetically profiled, pre-clinical model information that will help to accelerate drug discovery and development efforts."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.